((Automated translation by Reuters, please see disclaimer https://bit.ly/rtrsauto))
Nov. 18 – **Shares of drugmaker Eli Lilly LLY.N fall about 3.8% to $718.08, marking a fifth straight session of losses
** Evan Seigerman, analyst at BMO Capital Markets, says Lilly shares fell on the follow-up to Thursday's announcement of Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services social (US Department of Health and Human Services)
** Shares of obesity drug makers such as Novo Nordisk NOVOb.CO NVO.O and Lilly have fallen since the ruling
**Kennedy criticizes that these obesity drugs focus on symptoms rather than improving the food system
** Seigerman says Kennedy remains limited in his ability to influence policy or the price of obesity drugs
** Lilly shares are up 55% through October, making it the world's most valuable health care company
** Separately, Novo says it has launched its popular obesity drug, Wegovy, in China
**However, the drugmaker's U.S.-listed shares are down 1.5% at $100.20
**Throughout last close, LLY stock was up 23.9%, NVO was down 3% year-to-date
